Literature DB >> 24342721

Human relevance of NRAS/BRAF mouse melanoma models.

Alejandro Conde-Perez1, Lionel Larue2.   

Abstract

Melanoma is a major problem for many individuals worldwide. Although no effective treatment is available, promising new strategies are being developed. A better understanding of the inner workings of the disease would undoubtedly lead to improved treatments. Mouse melanoma models have been used to elucidate many key regulatory pathways involved in melanoma initiation and progression, and models with mutations in the oncogenes RAF and RAS have been particularly informative. Here, we summarize and evaluate the human relevance of various RAF and RAS mouse melanoma models and their contribution to our understanding of melanoma.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Initiation; Melanomagenesis; PTEN; Progression; p16(INK4A); β-Catenin

Mesh:

Substances:

Year:  2013        PMID: 24342721     DOI: 10.1016/j.ejcb.2013.10.010

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  7 in total

1.  Anti-tumor properties of cis-resveratrol methylated analogs in metastatic mouse melanoma cells.

Authors:  Valery L Morris; Tayyaba Toseef; Fathima B Nazumudeen; Christian Rivoira; Carmela Spatafora; Corrado Tringali; Susan A Rotenberg
Journal:  Mol Cell Biochem       Date:  2015-01-08       Impact factor: 3.396

Review 2.  Melanoma models for the next generation of therapies.

Authors:  E Elizabeth Patton; Kristen L Mueller; David J Adams; Niroshana Anandasabapathy; Andrew E Aplin; Corine Bertolotto; Marcus Bosenberg; Craig J Ceol; Christin E Burd; Ping Chi; Meenhard Herlyn; Sheri L Holmen; Florian A Karreth; Charles K Kaufman; Shaheen Khan; Sebastian Kobold; Eleonora Leucci; Carmit Levy; David B Lombard; Amanda W Lund; Kerrie L Marie; Jean-Christophe Marine; Richard Marais; Martin McMahon; Carla Daniela Robles-Espinoza; Ze'ev A Ronai; Yardena Samuels; Maria S Soengas; Jessie Villanueva; Ashani T Weeraratna; Richard M White; Iwei Yeh; Jiyue Zhu; Leonard I Zon; Marc S Hurlbert; Glenn Merlino
Journal:  Cancer Cell       Date:  2021-02-04       Impact factor: 31.743

3.  Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis.

Authors:  Charles-Antoine Assenmacher; Sara F Santagostino; Mark A Oyama; Jean-Christophe Marine; Elise Bonvin; Enrico Radaelli
Journal:  J Histochem Cytochem       Date:  2020-12-07       Impact factor: 2.479

4.  Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population.

Authors:  Małgorzata Mackiewicz-Wysocka; Patrycja Czerwińska; Violetta Filas; Elżbieta Bogajewska; Agata Kubicka; Anna Przybyła; Ewelina Dondajewska; Tomasz Kolenda; Andrzej Marszałek; Andrzej Mackiewicz
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

Review 5.  Cutaneous Melanoma-A Long Road from Experimental Models to Clinical Outcome: A Review.

Authors:  Dorina Coricovac; Cristina Dehelean; Elena-Alina Moaca; Iulia Pinzaru; Tiberiu Bratu; Dan Navolan; Ovidiu Boruga
Journal:  Int J Mol Sci       Date:  2018-05-24       Impact factor: 5.923

6.  Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model.

Authors:  Shuyang S Qin; Booyeon J Han; Alyssa Williams; Katherine M Jackson; Rachel Jewell; Alexander C Chacon; Edith M Lord; David C Linehan; Minsoo Kim; Alexandre Reuben; Scott A Gerber; Peter A Prieto
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

7.  Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma.

Authors:  Hussein Akil; Mercedes Quintana; Jérémy H Raymond; Tommy Billoux; Valentin Benboubker; Sophie Besse; Philippe Auzeloux; Véronique Delmas; Valérie Petit; Lionel Larue; Michel D'Incan; Françoise Degoul; Jacques Rouanet
Journal:  Cancers (Basel)       Date:  2021-03-20       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.